Abstract:The liver is a critical system for metabolism in human beings, which plays an essential role in an abundance of physiological processes and is vulnerable to endogenous or exogenous injuries. After the damage to the liver, a type of aberrant wound healing response known as liver fibrosis may happen, which can result in an excessive accumulation of extracellular matrix (ECM) and then cause cirrhosis or hepatocellular carcinoma (HCC), seriously endangering human health and causing a great economic burden. However, few effective anti-fibrotic medications are clinically available to treat liver fibrosis. The most efficient approach to liver fibrosis prevention and treatment currently is to eliminate its causes, but this approach’s efficiency is too slow, or some causes cannot be fully eliminated, which causes liver fibrosis to worsen. In cases of advanced fibrosis, the only available treatment is liver transplantation. Therefore, new treatments or therapeutic agents need to be explored to stop the further development of early liver fibrosis or to reverse the fibrosis process to achieve liver fibrosis resolution. Understanding the mechanisms that lead to the development of liver fibrosis is necessary to find new therapeutic targets and drugs. The complex process of liver fibrosis is regulated by a variety of cells and cytokines, among which hepatic stellate cells (HSCs) are the essential cells, and their continued activation will lead to further progression of liver fibrosis. It has been found that inhibiting HSC activation, or inducing apoptosis, and inactivating activated hepatic stellate cells (aHSCs) can reverse fibrosis and thus achieve liver fibrosis regression. Hence, this review will concentrate on how HSCs become activated during liver fibrosis, including intercellular interactions and related signaling pathways, as well as targeting HSCs or liver fibrosis signaling pathways to achieve the resolution of liver fibrosis. Finally, new therapeutic compounds targeting liver fibrosis are summarized to provide more options for the therapy of liver fibrosis.

Liver sinusoidal endothelial cells as potential drivers of liver fibrosis (Review)

Liver Sinusoidal Endothelial Cell: An Important Yet Often Overlooked Player in the Liver Fibrosis

Liver Sinusoidal Endothelial Cells Are Implicated in Multiple Fibrotic Mechanisms

Regulatory Long Non-Coding RNAs of Hepatic Stellate Cells in Liver Fibrosis (Review)

The Endothelium as a Driver of Liver Fibrosis and Regeneration

SECs (Sinusoidal Endothelial Cells), Liver Microenvironment, and Fibrosis

Liver Sinusoidal Endothelial Cells in Hepatic Fibrosis

Role of liver sinusoidal endothelial cells in the development and progression of liver fibrosis and related therapeutic strategy

Role of liver sinusoidal endothelial cell in metabolic dysfunction-associated fatty liver disease

Intercellular crosstalk of liver sinusoidal endothelial cells in liver fibrosis, cirrhosis and hepatocellular carcinoma

Liver Sinusoidal Endothelial S1pr2 Regulates Experimental Liver Fibrosis Through YAP/TGF‐β Signaling Pathway

Capillarized Liver Sinusoidal Endothelial Cells Undergo Partial Endothelial-Mesenchymal Transition to Actively Deposit Sinusoidal ECM in Liver Fibrosis

Transcriptome Analyses of Liver Sinusoidal Endothelial Cells Reveal a Consistent List of Candidate Genes Associated with Endothelial Dysfunction and the Fibrosis Progression

The Crosstalk Between Liver Sinusoidal Endothelial Cells and Hepatic Microenvironment in NASH Related Liver Fibrosis

Liver fibrosis and hepatic stellate cells: Etiology, pathological hallmarks and therapeutic targets

Liver Fibrosis Resolution: from Molecular Mechanisms to Therapeutic Opportunities

Targeting Liver Sinusoidal Endothelial Cells: An Attractive Therapeutic Strategy to Control Inflammation in Nonalcoholic Fatty Liver Disease

Precise Cell Therapy for Liver Fibrosis: Endothelial Cell and Macrophage Therapy

Novel Therapeutic Targets in Liver Fibrosis

The role of liver sinusoidal endothelial cells in cancer liver metastasis.